Safety and Efficacy of Empagliflozin in Hemodialysis (NCT05786443)
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Empagliflozin Among Patients Initiating Hemodialysis for the Treatment of End-Stage Kidney Disease
🩺 Plain-English Summary (8th-Grade Level)
A 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.
Who can join: Review the eligibility criteria below.
Location: Brigham and Women's Hospital — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Brigham and Women's Hospital — Boston, Massachusetts
- NYU Langone Health — New York, New York
📞 Contact the Study Coordinator
Phone: (617) 935-1572
Email: David.Charytan@nyulangone.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in End Stage Renal Disease
- Light Therapy in End Stage Kidney Disease — Philadelphia, Pennsylvania
- Ferric Citrate in ESRD Pilot Project — Houston, Texas
- Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients — Washington D.C., District of Columbia
- Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease — New York, New York
- Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis — San Antonio, Texas
- PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis — Washington D.C., District of Columbia
Explore by condition: All End Stage Renal Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.